8-K filing — GALECTIN THERAPEUTICS INC (GALT)
Filed: 2026-08-14 AccNo: 0001140361-26-032946 Size: 887 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 16.67 percent decrease over losses of $(0.12) per
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 12:13 PM
- Checked
- Aug 14, 2026, 12:13 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per Share
Galectin Therapeutics Inc. (NASDAQ:GALT) ("Galectin" or the "Company"), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and
Read original at benzingaGoldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday
Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.
Read original at benzinga